Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Expands Stock Repurchase Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics today said that its board of directors has authorized the repurchase of an additional $100 million of the firm's outstanding common stock.

The Salt Lake City-based molecular diagnostics firm already repurchased $100 million of its common stock under the initial repurchase program started this past May. It plans to repurchase the additional shares on the open market or through privately negotiated purchases and expects to complete the program by June 30, 2011.

"The expansion of our stock repurchase program reflects our confidence in the long-term potential for Myriad Genetics and our commitment to increasing shareholder value by returning capital to our shareholders," Myriad CFO James Evans said in a statement.

In early Tuesday trade on the Nasdaq, shares of Myriad were up 1 percent at $15.80.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.